16 September 2026 editorial review · Item
Golimumab (anti-TNF): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: T1GER 52-week and 104-week follow-up checked. Stage-1 platform registration is a planned prevention test and cannot support onset-delay efficacy.
- Registry NCT07683026: NOT_YET_RECRUITING; updated 2026-07-06; enrollment 255 (ESTIMATED); primary completion 2032-09-01 (ESTIMATED); results not posted in retrieved record.
- Registry NCT02846545: COMPLETED; updated 2025-02-04; enrollment 84 (ACTUAL); primary completion 2019-05-21 (ACTUAL); results posted.
- Registry NCT03298542: COMPLETED; updated 2025-02-03; enrollment 8 (ACTUAL); primary completion 2020-12-21 (ACTUAL); results not posted in retrieved record.
- Registry NCT04729296: WITHDRAWN; updated 2021-12-02; enrollment 0 (ACTUAL); primary completion 2027-07-01 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: NEJMoa2006136; dc22-0908; 125289s146lbl.pdf.